Molecules | Free Full-Text | Transcription Factors as Therapeutic Targets in Chronic Kidney Disease
Bardoxolone methyl | 218600-53-4
Signaling pathways of chronic kidney diseases, implications for therapeutics | Signal Transduction and Targeted Therapy
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease | Signal Transduction and Targeted Therapy
Frontiers | Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect
CDDO-Me | Cell Signaling Technology
Figure 2 from Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties | Semantic Scholar
Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
The chemical structure of bardoxolone methyl. | Download Scientific Diagram
Pharmacodynamics of bardoxolone methyl. A, levels of NF- k B, cyclin... | Download Scientific Diagram
Figure 2 | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
Bardoxolone methyl (RTA 402) | ≥99%(HPLC) | IκB/IKK inhibitor | AdooQ®
Bardoxolone methyl - IκB/IKK - NF-κB - Reference Compounds Your lab for organic synthesis
Role of NF-κB, PI3K and AKT pathways in ASC-mediated... | Download Scientific Diagram
Molecules | Free Full-Text | Effect of Redox Modulating NRF2 Activators on Chronic Kidney Disease
Bardoxolone methyl
Bardoxolone methyl (RTA 402) | Nrf2 Activator | MedChemExpress
reta-10k_20171231.htm
Bardoxolone - an overview | ScienceDirect Topics
Schematic image of potential mechanism by which bardoxolone methyl... | Download Scientific Diagram
Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - ScienceDirect
